Dermatology specialist LEO Pharma A& is preparing to launch the interleukin-13 inhibitor tralokinumab for atopic dermatitis in the US in 2021, where it will compete against a well-entrenched rival, Sanofi and Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab). Leo announced on 9 July that the US Food and Drug Administration has accepted a biologics license application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis, with action expected in the second quarter of 2021.
A regulatory review in Europe is already underway, with an application accepted in June.
